Everolimus for Cancer With TSC1 or TSC2 Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02201212
Recruitment Status : Recruiting
First Posted : July 28, 2014
Last Update Posted : March 1, 2018
Novartis Pharmaceuticals
Information provided by (Responsible Party):
David Kwiatkowski, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2018
  Estimated Study Completion Date : January 2022